The deadly fungal infection Candida auris reared its head iin a Los Angeles healthcare facility and could be related to Covid-19 cases through the conservation of personal protective equipment strategies. Amplyx Pharmaceuticals is working to develop a first-line treatment for patients with invasive fungal infections caused by Candida.
Following negative interim data from the company’s experimental treatment for non-alcoholic steatohepatitis (NASH) and fibrosis, France’s GENFIT will discontinue the Phase III RESOLVE-IT study of elafibranor in this indication.
An antiviral drug developed by Glenmark Pharmaceuticals boosted the time it takes Covid-19 patients with mild to moderate symptoms to improve their health in a Phase III study.
Wilmington, Delaware-based Incyte Corporation announced data from the Phase III REACH3 trial of Jakafi (ruxolitinib) in patients with moderate or severe steroid-refractory or steroid dependent chronic graft-versus-host disease (GVHD).
The National Institutes of Health (NIH) announced plans to launch a “flurry” of large-scale clinical trials for treating Covid-19.
San Francisco-based Olema Oncology secured $54 million in an oversubscribed Series B financing round to support the development of the company’s lead breast cancer treatment as well as expand ongoing research and development programs.
AbbVie’s Rinvoq (upadacitinib) as a monotherapy hit both primary and all secondary endpoints in a second Phase III trial, Measure Up 2, in patients with moderate to severe atopic dermatitis.
In an ongoing online hearing before the House Committee on Energy and Commerce’s Oversight and Investigation subcommittee, executives from across the pharmaceutical industry outlined the steps their companies are taking to combat Covid-19 and restore the world to a sense of normalcy.
The University of Oxford suggested that the end of 2020 is possible for the availability of a Covid-19 vaccine candidate being developed with AstraZeneca, but expressed caution about the timeline.
One of medicine’s costliest treatment areas could become even more pricey as Biogen seeks to layer the company’s $750,000 spinal muscular atrophy drug on top of the $2.1 million-per-patient Novartis gene therapy Zolgensma.
